A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP (R-Pola-Glo)

  • Schmitt, Clemens (PI)
  • Krivic, Denis (Researcher)
  • Lichtenauer, Nina (Researcher)
  • Kühr, Thomas (Researcher)
  • Schneeweiß, Bruno (Researcher)
  • Piringer, Gudrun (Researcher)
  • Popp, Henning Detlef (Researcher)
  • Krenosz, K. J. (Researcher)
  • Ghanem, Riad (Researcher)
  • Solomianyi, Oleksii (Researcher)
  • Schwarz, Heike Kathleen (Researcher)
  • Kovacsova, Judita (Researcher)
  • Kausche, Lea Elisabeth (Researcher)
  • Stegemann, Maike (Researcher)
  • Klein, Katharina (Researcher)
  • Trathnigg, Nicolas (Researcher)

Project: Clinical studies › Clinical Study (Industry project)

Project Details

Description

A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP
Short titleR-Pola-Glo
StatusActive
Effective start/end date07.08.2023 → 03.01.2028

Collaborative partners

  • Johannes Kepler University Linz (lead)
  • Institut für Klinische Krebsforschung IKF GmbH (Project partner)
  • Arbeitsgemeinschaft Medikamentöse Tumortherapie gGmbH (Project partner)

Fields of science

  • 302024 Haematology
  • 302055 Oncology